Exenatide versus glibenclamide in patients with diabetes

Diabetes Technology and Therapeutics

Volumn 12, Issue 3, 2010, Pages 233-240

  Derosa, G ^a   Maffioli, P ^a   Salvadeo, S A T ^a   Ferrari, I ^a   Ragonesi, P D ^b   Querci, F ^c   Franzetti, I G ^d   Gadaleta, G ^e   Ciccarelli, L ^f   Piccinni, M N ^g   D'Angelo, A ^a   Cicero, A F G ^h  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

^c Alzano Lombardo   (Italy)

^d OSPEDALE DI CIRCOLO   (Italy)

^e Civic Hospital   (Italy)

^f RSA Don Leone Porta   (Italy)

^g Fondazione Ospedale Della Caritá   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EXENDIN 4; GLIBENCLAMIDE; HEMOGLOBIN A1C; RESISTIN; RETINOL BINDING PROTEIN 4;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; PROINSULIN; RESISTIN; RETINOL-BINDING PROTEINS, PLASMA; VENOMS; YOUNG ADULT;

EID: 77249090274     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0141     Document Type: Article

References (46)

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
2. Tourrel C, Bailbé D, Meile MJ, Kergoat M, Portha B: Glucagon- like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin- treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50:1562-1570.
3. Hui H, Nourparvar A, Zhao X, Perfetti R: Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 50-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003;144:1444-1455.
4. Perfetti R, Zhou J, Doyle ME, Egan JM: Glucagon-like peptide- 1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000;141:4600-4605.
5. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-3723. (Pubitemid 32755966)
6. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagonlike peptide-1 by human plasma in vitro yields an Nterminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-957.
7. Triplitt CL: New technologies and therapies in the management of diabetes. Am J Manag Care 2007;13(Suppl 2): 547-554.
8. Joint Formulary Committee: British National Formulary, 57th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2009.
9. Byetta (exenatide) injections [product insert]. San Diego, CA: Amylin Pharmaceuticals, Inc., 2008.
10. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100.
11. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea- treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635.
12. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091.
13. Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG: The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-485.
14. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME: Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007;29:139-153.
15. Rendell M: The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339-1358.
16. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyö räläK, Raz I, Schernthaner G, Volpe M, Wood D; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD): Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
17. Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186-2191.
18. Bunn HF, Gabbay KH, Gallop PM: The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978;200:21-27.
19. European Diabetes Policy Group: A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-730.
20. Heding LG: Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972;8:260-266.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
22. Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.
23. Houssa P, Dinensen B, Deberg M, Frank BH, Van Schravendijk C, Sodoyez-Goffaux F, Sodoyez J-C: First direct assay for intact human proinsulin. Clin Chem 1998;44:1514-1519.
24. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS: Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003;88:1730-1736.
25. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inumai T: Retinol binding protein-4 and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007;92:2712-2719.
26. Rifai N, Tracy RP, Ridker PM: Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136-2141.
27. Winer BJ: Statistical Principles in Experimental Design, 2nd ed. New York: McGraw-Hill, 1971.
28. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-569.
29. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME: Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29:2333-2348.
30. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M: A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a noninferiority study. Diabetologia 2007;50:259-267.
31. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
32. Barnett A, Allsworth J, Jameson K, Mann R: A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin 2007;23:1493-1507.
33. Maggio CA, Pi-Sunyer FX: Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003;32:805-822.
34. Bray GA: Medical consequences ofobesity. J Clin Endocrinol Metab 2004;89:2583-2589.
35. Yki-Järvinen H, Westerbacka J: The fatty liver and insulin resistance. Curr Mol Med 2005;5:287-295.
36. Song Y, Manson JE, Tinker L, Howard BV, Kuller LH, Nathan L, Rifai N, Liu S: Insulin sensitivity and insulin secretion determined by homeostasis model assessment (HOMA) and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative observational study. Diabetes Care 2007;30:1747-1752. (Pubitemid 47036347)
37. Li YB, Zhu DL, Tian HM, Shi LX, Luo ZJ, Yan L, Zeng LY, Zhou ZG, Yang LY, Liu J, Li M, Weng JP: Characteristics of dysfunction of islet beta-cell in newly diagnosed type 2 diabetic patients [in Chinese]. Zhonghua Yi Xue Za Zhi 2006;86:2537-2541.
38. Pfützner A, Pfützner AH, Larbig M, Forst T: Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther 2004;6:405-412. (Pubitemid 38821628)
39. Moretto TJ, Milton DR, Ridge TD, MacConell LA, Okerson T, Wolka AM, Brodows RG: Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drugnaive patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448-1460.
40. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
41. Satoh H, Nguyen MT, Miles PD, Imamura T, Usui I, Olefsky JM: Adenovirus-mediated chronic 'hyper-resistinemia' leads to in vivo insulin resistance in normal rats. J Clin Invest 2004;114:224-231.
42. Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA: Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 2004;53:1937-1941.
43. Reilly MP, Lehrke M, Wolfe M, Rohatgi A, Lazar MA, Rader DJ: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-939.
44. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS: Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006;29:2457-2461.
45. Zwacka TP, Hornbach V, Torzewski J: C-reactive proteinmediated lipoprotein uptake by macrophages. Circulation 2001;103:1194-1197.
46. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian R, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ: One-year treatment with exenatide improves b-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients. Diabetes Care 2009;32:762-768.